Announcements Trials
Browse Landscape

Phase

Phase 3 8Phase 2 2Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1

Interventions

Specimen Handling 273Magnetic Resonance Spectroscopy 224pembrolizumab 214Carboplatin 173Biopsy 166Cisplatin 159Nivolumab 149Cyclophosphamide 133Radiotherapy 117Paclitaxel 117Gemcitabine 112Bevacizumab 92durvalumab 86Dexamethasone 80Rituximab 76Oxaliplatin 73atezolizumab 68Capecitabine 67venetoclax 66Fluorouracil 66Doxorubicin 65Docetaxel 65Etoposide 63Radiosurgery 60Radiation 57Prednisone 57Cytarabine 56Ipilimumab 55Pemetrexed 54Taxes 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Dactinomycin × 90 days × Clear all
NCT01871766 2026-04-24

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
115 enrolled
Sarcoma

Rhabdomyosarcoma

NCT04332874 2026-04-23

A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
30 enrolled
Sarcoma

Sarcoma, Dermatofibrosarcoma, Sarcoma, Alveolar Soft Part, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡